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Abstract
Background: This case report describes a patient with pericarditis likely attributed to influenza vaccination (positive
rechallenge), with a literature review.
Case presentation: A 87-year old patient developed pericarditis after influenza vaccination, with acute chest pain,
without ECG abnormalities or increased cardiac enzyme levels. Echocardiogram showed moderate pericardial
effusion. Recovery was obtained through steroids One year later, few days after re-immunization, the patient
experienced the same symptoms and was admitted to hospital with diagnosis of recurrence of pericarditis with
severe pericardial effusion, again treated with steroids. Other possible causes were ruled out and the cardiologist
recommended against influenza vaccinations in the future; the patient did not experience recurrence of pericarditis
in the following 6 years. Cases of pericarditis following influenza immunization in the literature were also reviewed.
Conclusions: Pericarditis following immunization for influenza is very rarely reported in the literature. In a few
cases, influenza vaccination seems likely responsible. We suggest considering recent immunization in patient’s
history as part of the differential diagnosis in elderly with chest pain.
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Background
Cardiac complications after immunization are extremely
rare events, albeit clinically important. In the past, the
association between an increased risk of myocarditis and
the use of smallpox vaccine, both in military personnel
and civilians, drew the attention of clinicians and
regulators [1]. Cases of myocarditis, pericarditis or myo-
pericarditis after other vaccines, including multiple
immunization have been reported as well, but a definite
association was never demonstrated [2–4]. Here below,
we describe a case of established pericarditis in an eld-
erly patient following seasonal influenza vaccine with
unintentional re-challenge. A 6-year follow-up free of
vaccine is also reported. A MEDLINE review was also
performed in February 2017 to discuss published case
reports/series.
Case presentation
On September 2008 a 87-year-old man was admitted to
hospital with diffuse, worsening (especially at night)
chest pain for several days (Fig. 1). His past history
included thyroidectomy, acute myocardial infarction and
total atrioventricular block with sick sinus syndrome for
which a single-chamber pacemaker was implanted and
subsequently upgraded to dual-chamber pacemaker
(because of pacemaker syndrome). He was also affected
by chronic obstructive pulmonary disease (no treatment
reported) and mild chronic kidney failure. Five months
before (April 2008) he had been admitted to hospital for
worsening heart failure due to acute pneumonia; atrial
fibrillation also had occurred and warfarin was started.
In the emergency department, physical examination
revealed diminished heart sounds, while chest X-rays
showed cardiomegaly. No ECG abnormalities or in-
creased cardiac enzyme levels were found. The primary
diagnosis was heart failure due to coronary insufficiency
and nitroglycerin provided rapid relief.
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Three months later (December 2008), in a follow-up
visit echocardiogram showed moderate pericardial effu-
sion without signs of tamponade (Fig. 2). Steroid therapy
(prednisone 40 mg/day with tapering for 1 month) was
initiated because of colchicine-related gastrointestinal
toxicity (discontinued early after first administration).
T. pallidum immunoglobulin G (IgG)/IgM antibody,
hepatitis-C virus IgG antibody, hepatitis-B virus surface
antigens and human immunodeficiency virus p24-antigen
and antibodies were negative.
One year later (October 2009), the patient’s conditions
worsened due to onset of chest pain and dyspnea and,
on hospital admission, echocardiography confirmed peri-
carditis with severe pericardial effusion; steroid therapy
(as above) was resumed and after 4 months pericardio-
centesis was performed.
In April 2010 the patient was again admitted to
hospital for pericarditis relapse and knee-arthritis with
important synovial effusion. Periocardiocentesis was
repeated and 750 cm3 of serosanguineous fluid was
drained; arthrocentesis was also performed. Fluid
cultures were both negative for aerobic and anaerobic
bacteria. Mycobacteria culture and Quantiferon test
were negative for tuberculosis infection as well as
cytologic test for malignant cells.
In order to find out the possible cause of pericarditis, a
careful history ascertained that the patient had received
influenza vaccine (Influvac®,trivalent, inactivated) 5–7 days
before the first admission; the patient reported re-
immunization with influenza vaccine (unknown name and
typology) also one year later, just some days before the
second admission to hospital. In the absence of other pos-
sible causes (infectious diseases, autoimmune diseases,
cancer, drugs), hypothesis of pericarditis and recurrence
caused by influenza vaccine was therefore considered. Fol-
lowing the last hospital admission the cardiologist in
charge recommended against influenza vaccinations in the
future and the patient did not experience recurrence of
pericarditis in the following 6 years of follow-up.
Fig. 1 Timeline of events
Fig. 2 Transthoracic echocardiogram (M-Mode, subcostal
four-chamber and apical four-chamber view) showing moderate
pericardial effusion (arrows)
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Discussion and conclusions
Annual vaccination is an important public health measure
to prevent influenza because influenza viruses change
their antigenic characteristics frequently and may easily
spread in the population [5–8]. In particular, elderly popu-
lation (≥65 years old) and individuals with underlying dis-
eases have either higher risk of complications of influenza
and death. In these categories, influenza vaccine re-
duces dramatically both influenza occurrence and the
severity of the illness [9, 10]. Moreover, influenza vac-
cine in older people is associated with a lower risk of
cardiovascular events, especially in those with underlying
cardiovascular risk factors (e.g. coronary disease) [11]. An-
nual immunization against influenza also reduces risk of
death particularly in previously immunized [12] subjects.
Pericarditis typically presents with chest pain (> 85–90%
of cases), pericardial friction rub (≤33% of cases), ECG
changes (up to 60% of cases), increased cardiac en-
zymes and markers of inflammation (i.e. C-reactive
protein, erythrocyte sedimentation rate and white blood
cell count). Recurrent pericarditis is diagnosed when a
symptom-free interval of 4–6 weeks or longer separates
the first episode of pericarditis. Recurrence occurs in
15–30% of cases after an initial episode, and may in-
crease to 50% after a first recurrence in patients not
treated with colchicine, particularly if treated with
corticosteroids [13].
We searched MEDLINE in February 2017 for case re-
ports/series, by combining the following key-words: “in-
fluenza”, “vaccine”, “immunization” and “pericarditis”,
without language restrictions. Six case reports (7 pa-
tients) of pericarditis after influenza immunization were
identified: of these, 4 patients aged more than 60 years,
mean time of symptom onset was 7 days, outcome was
favorable in all the cases (recovery). According to the
authors, a positive association between pericarditis and
vaccine was defined in 4 cases, while 3 cases resulted
with a “possible” association. In only one case, recur-
rence of pericarditis after influenza immunization
reported, about 2 years after the first episode. Further
details are shown in Table 1. Only one case described a
patient with recurrent pericarditis after influenza vac-
cination in two consecutive years [14]. Interestingly,
Zanettini et al. compared 84 patients with pericarditis,
divided into two groups; patients immunized with influ-
enza vaccine, compared with patients not immunized,
had a typical seasonal distribution with a peak in autumn,
fewer comorbidities, less exuberant signs and symptoms,
and clinical relief with NSAIDs use [15]. Considering the
widespread use of influenza vaccination (approximately
two of every five children and adults in the United States
were vaccinated by early November 2016) [16], the occur-
rence of iatrogenic pericarditis is an extremely rare com-
plication. However, in the light of the described event and
the series reported by Zanettini et al., we cannot exclude
that similar cases may be underestimated since the cause
of more than a half pericarditis (86.0% reported by
Permanyer-Miralda et al., 78.0% reported by Zayas et al.
and 83.2% reported by Imazio et al.) [17–19] remains
undetermined.
We described a rare case of pericarditis following
immunization, which did not meet the typical clinical
and laboratory presentation. The underlying chronic dis-
eases of the elderly patient (ischemic cardiomyopathy,
permanent atrial fibrillation, chronic obstructive pul-
monary disease and mild chronic kidney failure) do not
fully explain pericarditis, although they probably contrib-
uted to its appearance (e.g. use of anticoagulant therapy).
We cannot exclude that a recurrent viral infection could
have caused the pericarditis episodes, because no spe-
cific viral studies were performed to systematically rule
out viral etiologies of pericarditis. Nonetheless, hepatitis
and HIV infections were excluded, as well as bacterial in-
fections, since laboratory data and pericardial fluid culture
were negative. These findings, together with positive re-
challenge (re-administration one year after the first event
with event re-occurrence) are key elements to define the
association with influenza vaccine as “correlated” by
Table 1 MEDLINE search results for pericarditis after influenza vaccination





1981 61 F Recurrent pericarditis 7 days Yes Favorable [14]
1997 40 M Pericarditis 5 days Yes Favorable [22]
2000 75 M;40 M Pericarditis 6 days; 5 days Yes Favorable (both) [23]
2003 87 M Pericarditis 5 days Possible Favorable [24]
2004 68 F Pericarditis and Guillain-Barré syndrome 2 weeks Possible Favorable [25]
2004 ≈60 (23 cases; 16F and 7 M) Pericarditis Not reported Yes Favorable [15]
2008 59F Pericarditis, pancytopenia, autoimmune
haemolytic anemia, hepatitis and nephritis
due to systemic systemic lupus erythematosus
flare-up
1 month Possible Favorable [26]
Mei et al. BMC Pharmacology and Toxicology  (2018) 19:20 Page 3 of 5
WHO-AEFI (Adverse event Following Immunization)
algorithm [20]. Moreover, the patient was monitored for
the following 6 years during which influenza vaccination
was not performed and no recurrence of pericarditis was
reported (positive de-challenge). This is in line with Engler
et al. [21] who strengthened the importance of active
long-term surveillance.
In conclusion, although under-reporting can be sup-
posed, the rarity of pericarditis after immunization does
not affect the already established positive benefit-risk
profile of influenza vaccine (and of vaccines in general).
However, considering the high prevalence of pericarditis
of undetermined origin, episodes of recent immunization
should be highlighted in patient’s history to support
differential diagnosis.
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